alirocumab vs fluvastatin
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of alirocumab and fluvastatin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Lescol
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Fluvastatin (Lescol) is a medicine that helps lower cholesterol levels in your blood. It belongs to a group of drugs called statins.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
This medicine is used to lower high cholesterol and triglycerides (fats) in adults and children (10-16 years old) with certain inherited cholesterol problems. It can also lower the risk of needing procedures to improve blood flow to the heart in adults with heart disease. Fluvastatin can also slow down the hardening of arteries in people with heart disease.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Fluvastatin works by blocking a substance your body needs to make cholesterol. This helps to lower bad cholesterol (LDL) and triglycerides while raising good cholesterol (HDL). By lowering cholesterol, it helps prevent heart disease and stroke.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Headache
- • Upset stomach
- • Muscle pain
- • Abdominal pain
- • Nausea
- Myalgia 1,655
- Product Dose Omission 1,364
- Injection Site Pain 1,278
- Muscle Spasms 1,162
- Arthralgia 1,053
- Myalgia 669
- Diarrhoea 371
- Dizziness 361
- Dyspnoea 340
- Nausea 337
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
This medicine can sometimes cause muscle problems, including rhabdomyolysis (a serious muscle breakdown that can lead to kidney damage). Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor should do blood tests to check your liver before you start taking fluvastatin and while you are taking it.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
You should not take fluvastatin if you are pregnant or breastfeeding. This medicine can harm an unborn baby. If you are a woman who could become pregnant, use effective birth control while taking fluvastatin.
Also Compare, Nearby Drugs
Compare alirocumab with
Compare fluvastatin with
How to Read This alirocumab vs fluvastatin Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while fluvastatin sits within the HMG-CoA Reductase Inhibitor (Statin) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while fluvastatin has 2,078. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alirocumab or fluvastatin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.